You get an ADC, you get an ADC: Pharmas bite on oncology’s buzziest class
MADRID — When Daiichi Sankyo scientists pushed forward with antibody-drug conjugate research nearly a decade ago, the program had a lot of naysayers, even inside the company.
Antibody-drug conjugates, or ADCs, were falling out of fashion, and much of the industry was moving on to other treatment types. “Why do we think that our ADCs are going to be any better than existing ones?” people thought at the time, according to Daiichi Sankyo R&D head Ken Takeshita, who joined the company later on in 2021.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.